Sumitovant Biopharma announced Urovant Sciences has entered into an exclusive three-year distribution agreement with Sunovion to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.
Urovant Sciences announced the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product ...